Vir Biotechnology (VIR) Competitors

Vir Biotechnology (NASDAQ:VIR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Which has higher valuation and earnings, VIR or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$74.21M	8.20	-$521.96M	-$4.00	-1.10
Catalyst Pharmaceuticals	$491.73M	5.12	$163.89M	$1.65	12.46

Do institutionals and insiders believe in VIR or CPRX?

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 16.0% of Vir Biotechnology shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is VIR or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 37.36% compared to Vir Biotechnology's net margin of -2,895.94%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-2,895.94%	-50.22%	-40.78%
Catalyst Pharmaceuticals	37.36%	40.78%	35.36%

Does the media favor VIR or CPRX?

In the previous week, Catalyst Pharmaceuticals had 8 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Catalyst Pharmaceuticals and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.40 beat Catalyst Pharmaceuticals' score of 1.14 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer VIR or CPRX?

Vir Biotechnology currently has a consensus target price of $30.25, indicating a potential upside of 590.64%. Catalyst Pharmaceuticals has a consensus target price of $33.20, indicating a potential upside of 61.48%. Given Vir Biotechnology's higher possible upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Catalyst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Which has more risk & volatility, VIR or CPRX?

Vir Biotechnology has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats Vir Biotechnology on 11 of the 17 factors compared between the two stocks.